These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 7819273)

  • 1. The biology of erbB-2/neu/HER-2 and its role in cancer.
    Hynes NE; Stern DF
    Biochim Biophys Acta; 1994 Dec; 1198(2-3):165-84. PubMed ID: 7819273
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase.
    Stancovski I; Sela M; Yarden Y
    Cancer Treat Res; 1994; 71():161-91. PubMed ID: 7946947
    [No Abstract]   [Full Text] [Related]  

  • 3. HER2/neu expression in cancer: the pathologist as diagnostician or prophet?
    Foster CS; Gosden CM; Ke Y
    Hum Pathol; 2003 Jul; 34(7):635-8. PubMed ID: 12874757
    [No Abstract]   [Full Text] [Related]  

  • 4. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy.
    Ross JS; Fletcher JA
    Semin Cancer Biol; 1999 Apr; 9(2):125-38. PubMed ID: 10202134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basic science of HER-2/neu: a review.
    Hung MC; Lau YK
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):51-9. PubMed ID: 10482194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER-2/neu receptor gene status in endometrial carcinomas: a tissue microarray study.
    Xu M; Schwartz P; Rutherford T; Azodi M; Santin A; Silasi D; Martel M; Hui P
    Histopathology; 2010 Jan; 56(2):269-73. PubMed ID: 20102407
    [No Abstract]   [Full Text] [Related]  

  • 7. Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission.
    Schiffer IB; Gebhard S; Heimerdinger CK; Heling A; Hast J; Wollscheid U; Seliger B; Tanner B; Gilbert S; Beckers T; Baasner S; Brenner W; Spangenberg C; Prawitt D; Trost T; Schreiber WG; Zabel B; Thelen M; Lehr HA; Oesch F; Hengstler JG
    Cancer Res; 2003 Nov; 63(21):7221-31. PubMed ID: 14612517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amplification of the C-erbB-2(HER-2/neu) proto-oncogene in ovarian carcinomas.
    Fan QB; Bian ML; Huang SZ; Lang JH; Ma J; Liu WS; Xu XY
    Chin Med J (Engl); 1994 Aug; 107(8):589-93. PubMed ID: 7805442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Los receptores epidérmicos humanos en el cáncer gástrico: alteraciones moleculares y su papel como diana terapéutica.
    Bustos-Carpinteyro AR; Magaña-Torres MT; González-García JR; Torres-Jasso JH; Sánchez-López JY
    Gac Med Mex; 2017; 153(7):830-840. PubMed ID: 29414960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steroid hormonal independence of HER-2/neu mRNA expression in four human ovarian carcinoma cell lines.
    Jones J; Lagasse LD; Karlan BY
    Gynecol Oncol; 1994 Dec; 55(3 Pt 1):421-6. PubMed ID: 7835782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The erbB2 gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A.
    Yu D; Hung MC
    Cancer Metastasis Rev; 1998 Jun; 17(2):195-202. PubMed ID: 9770116
    [No Abstract]   [Full Text] [Related]  

  • 12. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
    Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
    Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis.
    Xing X; Wang SC; Xia W; Zou Y; Shao R; Kwong KY; Yu Z; Zhang S; Miller S; Huang L; Hung MC
    Nat Med; 2000 Feb; 6(2):189-95. PubMed ID: 10655108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cancer gene therapy with plasmid expressing anti-HER2/neu-toxin].
    Khodarovich YM; Rakhmaninova DD; Kagarlitskiy GO; Deev SM
    Vopr Onkol; 2016; 62(5):671-675. PubMed ID: 30695596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
    Pegram MD; Finn RS; Arzoo K; Beryt M; Pietras RJ; Slamon DJ
    Oncogene; 1997 Jul; 15(5):537-47. PubMed ID: 9247307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness.
    Goebel SU; Iwamoto M; Raffeld M; Gibril F; Hou W; Serrano J; Jensen RT
    Cancer Res; 2002 Jul; 62(13):3702-10. PubMed ID: 12097278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Over-expression of erbB-2/neu is paralleled by inhibition of mouse-mammary-epithelial-cell differentiation and developmental apoptosis.
    Lazar H; Baltzer A; Gimmi C; Marti A; Jaggi R
    Int J Cancer; 2000 Feb; 85(4):578-83. PubMed ID: 10699933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy for cancer: the HER-2/neu and Herceptin story.
    Ross JS; Gray GS
    Clin Leadersh Manag Rev; 2003; 17(6):333-40. PubMed ID: 14692077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
    Konecny G; Pauletti G; Pegram M; Untch M; Dandekar S; Aguilar Z; Wilson C; Rong HM; Bauerfeind I; Felber M; Wang HJ; Beryt M; Seshadri R; Hepp H; Slamon DJ
    J Natl Cancer Inst; 2003 Jan; 95(2):142-53. PubMed ID: 12529347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance of HER-2/neu overexpression in patients with testicular nonseminomatous germ cell tumor.
    Ghavamnasiri MR; Saeedi Saedi H; Shahid Sales S; Ghafarzadegan K
    Urol J; 2010; 7(1):26-9. PubMed ID: 20209452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.